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Background: We previously reported the identification of ONC201/TIC10, a novel small molecule inducer of the human
TRAIL gene that improves efficacy-limiting properties of recombinant TRAIL and is in clinical trials in advanced cancers
based on its promising safety and antitumor efficacy in several preclinical models.
Methods: We performed a high throughput luciferase reporter screen using the NCI Diversity Set II to identify TRAIL-inducing
compounds.
Results: Small molecule-mediated induction of TRAIL reporter activity was relatively modest and the majority of the hit
compounds induced low levels of TRAIL upregulation. Among the candidate TRAIL-inducing compounds, TIC9 and
ONC201/TIC10 induced sustained TRAIL upregulation and apoptosis in tumor cells in vitro and in vivo. However,
ONC201/TIC10 potentiated tumor cell death while sparing normal cells, unlike TIC9, and lacked genotoxicity in normal
fibroblasts. Investigating the effects of TRAIL-inducing compounds on cell signaling pathways revealed that TIC9 and
ONC201/TIC10, which are the most potent inducers of cell death, exclusively activate Foxo3a through inactivation of
Akt/ERK to upregulate TRAIL and its pro-apoptotic death receptor DR5.
Conclusion: These studies reveal the selective activity of ONC201/TIC10 that led to its selection as a lead compound
for this novel class of antitumor agents and suggest that ONC201/TIC10 is a unique inducer of the TRAIL pathway
through its concomitant regulation of the TRAIL ligand and its death receptor DR5.
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Gene regulationIntroduction
TRAIL is an endogenous protein that induces fulminant
tumor-specific apoptosis through binding to death re-
ceptors DR4 or DR5 expressed in human tumor cells
[1]. TRAIL has received considerable attention since the
gene was first cloned because of its therapeutic potential* Correspondence: wafik.eldeiry@fccc.edu
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distinguish tumor from normal cells. TRAIL is naturally
expressed in a several human tissues and membrane-
bound TRAIL is also conditionally expressed in some
immune cells following cytokine stimulation [2-6].
Through its expression in such cells, TRAIL plays a direct
role in tumor suppression during immune surveillance
though this anticancer mechanism is lost during the dis-
ease progression.
The ability of TRAIL to initiate apoptosis selectively in
cancer cells has led to clinical trials with novel agents
that engage the TRAIL pathway, which includes recom-
binant TRAIL and TRAIL-agonist antibodies that targethis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ies have exhibited promising preclinical activity and
safety in early phase clinical trials [14]. Nevertheless,
these investigational therapies did not prove sufficiently
effective in clinical trials and the clinical development of
recombinant TRAIL has been halted. While the reasons
for clinical failure are not entirely clear, we and others
have highlighted several undesirable drug properties that
may hinder the efficacy of recombinant TRAIL such as
serum half-life, stability, and/or biodistribution.
Several experimental efforts to improve the efficacy of
TRAIL-targeted therapies have been reported. Recom-
binant TRAIL mutants that are remarkably more stable
have been identified [15], as well as variants that contain
leucine or isoleucine zippers to facilitate trimerization of
the soluble ligand, since receptor-bound TRAIL is tri-
meric [16,17]. We previously reported a novel class of
DR4-targeted proteins called DR4 Atrimers that are
engineered to mimic the conformation of trimeric
TRAIL bound to DR4 using a stable tetranectin scaffold
[18]. Mesenchymal stem cells overexpressing TRAIL
have been described in preclinical studies that improve
the biodistribution of TRAIL to enable activity against
glioma since the available TRAIL-based therapies do not
cross the blood–brain barrier [19]. In vitro characterization
and structure-activity relationships of small molecules
that induce DR5 clustering and activation have also be
reported [20].
TRAIL is a robust and selective tumor suppressor that
offers itself as an attractive natural drug target to restore
anti-tumor immunity. We hypothesized that upregula-
tion of TRAIL expression by a small molecule would
lead to a potent and novel anti-tumor mechanism by im-
proving suboptimal drug properties of recombinant
TRAIL. Regulation of the TRAIL gene has been de-
scribed for several transcription factors [21], most of
which are tumor suppressors such as p53 [22], and
Foxo3a [23]. We explicitly selected for TRAIL-inducing
compounds that upregulate TRAIL gene transcription
using a mechanism that does not rely on p53 due to its
frequent inactivation in late stage cancers that causes
resistance to many standard-of-care therapies [24]. To
identify small molecule p53-independent inducers of
the human TRAIL gene we conducted a small molecule
library screen using the NCI Diversity Set II. The
screen was conducted in HCT116 cells lacking the Bax
gene, which renders TRAIL resistance to allow for
assay readout [25], and stably expressing a luciferase
reporter of the human TRAIL gene promoter. Here we
describe the preclinical studies that led to the selection
of ONC201/TIC10 as the lead TRAIL-inducing com-
pound that we previously reported as a novel and po-
tent antitumor agent and has entered phase I clinical
trials in advanced cancers [26].Results
Screening for small molecules that induce TRAIL gene
promoter activity
We transiently transfected HCT116 Bax-null cells with a
luciferase gene reporter construct under transcriptional
control of the first 504 base pairs of the human TRAIL
gene promoter and selected for clones with stable expres-
sion. The NCI Diversity Set II was tested at 20 nM, 200
nM, 500 nM, and 1 μM using this cell-based reporter sys-
tem at 12, 24, 36, and 48 hours post-treatment. Overall
the small molecule library resulted in relatively modest
changes in the TRAIL gene reporter activity, with most
molecules causing a decrease in reporter activity due to
cytotoxic effects or repression of the reporter (Figure 1a).
We selected 29 compounds that induce >1.4-fold induc-
tion of reporter activity for further study. Normalizing
for change in cell viability, we found that 10 of these 29
compounds were able to upregulate TRAIL reporter ac-
tivity >2-fold under at least 2 of the tested conditions,
with most of this activity at a dose of 1 μM (Figure 1b-c).
TIC9 and ONC201/TIC10 induce TRAIL and apoptosis
in vivo
Nine of these 10 compounds that induce TRAIL gene
promoter reporter activity were selected for further
characterization, as TIC3 was unavailable at the time of
study (Figure 1d). Interestingly TIC9 is breflate, the pro-
drug of the small molecule brefeldin A that is a classic
ER stress-inducer. In general, these 9 small molecules
stimulated TRAIL gene promoter reporter activity in a
dose-dependent manner and at time points ≥24 hours
post-treatment (Figure 2a). RT-qPCR analysis of p53-
deficient HCT116 cells revealed that TIC4, TIC8, TIC9,
and ONC201/TIC10 were capable of upregulating
TRAIL messenger RNA levels under the tested condi-
tions in a p53-deficient background (Figure 2b). Next we
assessed the capability of these molecules to upregulate
TRAIL on the surface of tumor cells. TIC9 and
ONC201/TIC10 were the only compounds capable of
upregulating TRAIL protein at the surface of HCT116
cells under the tested conditions (Figure 2c).
The ability of TIC9 and ONC201/TIC10 to induce
TRAIL in vivo was assessed in subcutaneous xenografts
of HCT116 cells following a single intraperitoneal dose.
Messenger RNA harvested from tumor xenografts found
that TRAIL transcript levels were significantly elevated
by both TIC9 and ONC201/TIC10 compared to vehicle
treatment or TIC4 treatment, which was used as a nega-
tive control comparator (Figure 3a). Immunohistochemi-
cal analysis of treated tumor xenografts indicated that
TIC9 and ONC201/TIC10 also elevate TRAIL protein
levels in vivo (Figure 3b). Assessment of apoptosis in
treated tumor xenografts revealed that TIC9 induces cell
death as soon as the first day following treatment in
Figure 1 Identification of TRAIL-inducing compounds by high-throughput luciferase reporter screen. (a) Plot of reporter induction versus
signal for screen conducted with the NCI Diversity Set II at 1 μM in HCT116 Bax−/− cells that stably express a luciferase gene reporter construct
under transcriptional control of the first 504 base pairs of the human TRAIL gene promoter. Induction is expressed as luminescence relative to DMSO-treated
cells. The horizontal red line represents the cutoff for selection. (b) Validation of reporter induction for candidate screen hits in HCT116 Bax−/− cells at multiple
doses and time points. Reporter signal is expressed relative to DMSO-treated cells and normalized to cell viability. The horizontal red line represents the cutoff
for selection. Data represent an average of three replicates. The horizontal red line represents the cutoff for selection. (C) Molecular structures of the selected
TRAIL-inducing compounds.
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of apoptosis at day 3 (Figure 3c-d). Interestingly, TIC4 also
induces significant levels of apoptosis in a time-dependent
manner that suggests the molecule may have TRAIL-
independent pro-apoptotic effects on tumors in vivo.
Based on the ability of TIC9 and ONC201/TIC10 to in-
duce TRAIL and apoptosis in tumor xenografts, we per-
formed an in vivo study to assess the antitumor activity of
these two small molecules by bioluminescent imaging of
luciferase-infected HCT116 subcutaneous xenografts. Ad-
ministration of a single dose of ONC201/TIC10 potently
inhibited the tumor signal following administration of a
single dose (Figure 3e). TIC9 also inhibited the biolumin-
escent signal of the tumor compared to vehicle-treated xe-
nografts but was inferior to ONC201/TIC10 under the
tested conditions.Selection of ONC201/TIC10 as a lead TRAIL-inducing
compound
A time-course analysis of cell death in HCT116 cells indi-
cated that TIC9 and ONC201/TIC10 were exclusively
capable of inducing cell death. In accordance with our
other studies, ONC201/TIC10 induced a delayed and
modest amount of cell death that was apparent at 72 hours
post-treatment with a 1 μM dose (Figure 4a-b). Interest-
ingly, TIC4 did not induce tumor cell death under these
conditions despite the observation that the molecule in-
duced apoptosis in vivo. Together, these observations sug-
gest that TIC4 may have TRAIL-independent apoptotic
activity that depends on physiological factors not present
in vitro or requires higher doses. Assessing slightly higher
doses of TRAIL-inducing compounds in the low micro-
molar range revealed that both TIC9 and ONC201/TIC10
Figure 2 TIC9 and ONC201/TIC10 induce TRAIL gene transcription and surface TRAIL upregulation in tumor cells in vitro. (a) Reporter
activity in HCT116 Bax−/− cells that stably express a luciferase gene reporter construct under transcriptional control of the first 504 base pairs of
the human TRAIL gene promoter (n = 3). Reporter signal is expressed relative to DMSO-treated cells and normalized to cell viability. (b) RT-qPCR
analysis of TRAIL gene transcription in response to TRAIL-inducing compounds (TICs) (5 μM) in HCT116 p53−/− cells (n = 4, 48 hr). (c) Flow cytometry
analysis of surface TRAIL in response to TICs (5 μM) in HCT116 p53−/− cells (n = 3, 72 hr). *P < .05 by student’s two-tailed t test. Error bars represent
standard deviation.
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tent in p53-deficent human tumor cells (Figure 4c). Assay-
ing the effects of the same cytotoxic dose on normal
human fibroblasts revealed that TIC9 also induced signifi-
cant levels of cell death in these cells (Figure 4d). However
ONC201/TIC10 did not induce any appreciable levels of
cell death in normal cells under the same conditions that
were cytotoxic to tumor cells, suggesting a favorable
therapeutic window.
Parallel cell viability assays with normal and tumor
cells confirmed that ONC201/TIC10 has a wide thera-
peutic window. ONC201/TIC10 eliminated tumor cells
in vitro with a dose–response relationship that was
steep, saturable, and much more potent against tumor
cells than normal cells (Figure 4e). Despite lack of induc-
tion of apoptosis in normal cells, ONC201/TIC10 ap-
pears to modestly inhibit the proliferation of normal
cells at higher micromolar dose and an GI50 was not
reached. We evaluated the potential effects of ONC201/TIC10 on normal cell morphology and genotoxicity by
microscopy. Immunofluorescence experiments revealed
that ONC201/TIC10 does not induce changes in the
morphology or levels of gamma-H2AX in normal cells,
unlike the DNA-damaging chemotherapy doxorubicin,
despite long-term incubation with doses that are cytotoxic
to tumor cells (Figure 5). A similar lack of genotoxicity or
alteration of normal cell morphology was observed at
lower doses of ONC201 as well (data not shown). To-
gether these studies rationalize the selection of ONC201/
TIC10 as a lead TRAIL-inducing compound that upregu-
lates TRAIL gene transcription and protein levels, induces
tumor-specific cell death, and is not cytotoxic or geno-
toxic to normal cells (Figure 6).
Cytotoxic TRAIL-inducing compounds exclusively active
Foxo3a
Our previous studies with ONC201/TIC10 demonstrate
that the small molecule induces TRAIL and TRAIL-
Figure 3 TIC4, TIC9, and ONC201/TIC10 upregulate TRAIL in vivo. (a) RT-qPCR analysis of HCT116 p53−/− tumor xenograft in athymic nude
mice harvested 2 days following a single intravenous dose of DMSO, TIC4, TIC9, or ONC201/TIC10 (25 mg/kg). *P < .05 by student’s two-tailed t test. (b)
IHC analysis of TRAIL protein levels in HCT116 p53−/− tumor xenograft in athymic nude mice harvested following a single intravenous dose of DMSO,
TIC4, TIC9, or ONC201/TIC10 (25 mg/kg). (c) Exemplary images and (d) quantification of TUNEL staining in TIC-treated xenograft tumors described in (a).
(e) Bioluminescent imaging of luciferase-infected HCT116 subcutaneous xenografts following a single intraperitoneal dose of TIC9 and ONC201/TIC10
(100 mg/kg) on day 0. Quantification of tumor signals shown in right panel (n = 6). Error bars represent standard deviation.
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vation Foxo3a, which directly regulates TRAIL gene
transcription at its gene promoter. Western blot analysis
revealed that several of the TRAIL-inducing compoundsreduced levels of phospho-Akt (Figure 7). Among the top
TRAIL-inducing compounds, only TIC9 and ONC201/
TIC10 inhibited phospho-ERK levels and caused the de-
phosphorylation of Foxo3a that is associated with its
Figure 4 TIC9 and ONC201/TIC10 induce tumor cell death and ONC201/TIC10-induced cell death is tumor-selective. (a) Sub-G1 DNA
content of HCT116 p53−/− cells treated with TICs for indicated time periods (1 μM, n = 3). (b) Cell cycle profiles of HCT116 p53−/− cells treated
with TICs (5 μM, 72 hr). (c) Sub-G1 DNA content of HCT116 p53−/− cells treated with TICs (72 hrs, 5 μM, n = 3). (d) Sub-G1 DNA content of HFF normal
human fibroblasts treated with TICs (72 hr, 5 μM, n = 3). (e) Cell viability assay of HCT116 or HFF cells treated with ONC201/TIC10 at the indicated doses
(72 hr, n = 3). Error bars represent standard deviation.
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thermore, TIC9 and ONC201/TIC10 were the only mole-
cules that upregulated DR5, which is also a Foxo3a target
gene that may contribute to the sensitivity of tumor cells
to ONC201/TIC10-induced TRAIL. The observation that
the exclusively cytotoxic TRAIL-inducing compounds also
exclusively activate Foxo3a suggests that Foxo3a is a
uniquely proapoptotic regulator of TRAIL-mediated apop-
tosis among other TRAIL gene regulators. Concomitant
induction of TRAIL and DR5 by Foxo3a and perhaps
other transcriptional mechanisms may explain the ability
of ONC201/TIC10 to induce significant levels of apoptosis
with modest induction of the ligand.
Discussion
The magnitude and time points for kinetics of TRAIL in-
duction observed in the screen for TRAIL-inducing com-
pounds indicate that regulation of the TRAIL gene may be
tightly controlled, perhaps due to its potent apoptotic po-
tential. Chemical derivatives may be explored to improve
TRAIL-inducing compounds in terms of potency and
magnitude of TRAIL induction as well as potentially un-
veil structure-activity relationships. The observation that
TIC9 and ONC201/TIC10 uniquely affect Akt- and ERK-mediated phosphorylation of Foxo3a is particularly inter-
esting, given their exclusive ability to induce cancer cell
death among the TRAIL-inducing compounds. While the
two molecules are very diverse in structure and likely dif-
fer in other effects on cell signaling, this common effect
suggests that Foxo3a may be an attractive transcriptional
mechanism for inducing the TRAIL gene as an anticancer
therapeutic mechanism.
While our first report of ONC201/TIC10 was in prepar-
ation, another report was published that described another
novel class of small molecules that are capable of engaging
the TRAIL death receptor pathway [20]. Identified in
other efforts aiming to find small molecule Smac mi-
metics, Wang et al. reported a small molecule, bioymifi,
that induces the clustering of DR5 and activation of its
downstream apoptotic signaling. This novel therapeutic
approach holds promise a new class of TRAIL-based
agents, though its spectrum of activity and in vivo activity
will need to be evaluated in future studies.
TRAIL-inducing compounds are a novel class of
TRAIL-based therapy that engage tumors and the host
system to upregulate TRAIL and potentially sensitize
tumor cells to its pro-apoptotic activity through dual
death receptor and ligand induction, as seen with TIC9
Figure 5 ONC201/TIC10 is not genotoxic to normal human fibroblasts. (a) Bright field microscopy images of HFF fibroblasts following 72 hr
incubation with DMSO, ONC201/TIC10, or doxorubicin (1 μM) as indicated. (b) Immunofluorescence imaging of gamma H2AX (green) and nuclear
counterstain (blue) in HFF fibroblasts treated as described in (a).
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reported to induce DR5 as a mechanism of tumor cell
sensitization to TRAIL-mediated apoptosis [27]. Though
p53 can also regulate the DR5 gene [28], both ONC201/
TIC10 [26] and brefledin A [29], which TIC9 is a pro-
drug of, possess p53-independent anti-cancer activity
that suggests DR5 induction occurs through other tran-
scription factors. p53-independent induction of DR5 in
tumor cells has been confirmed for ONC201 [26]. While
both the TRAIL and DR5 gene promoters contain
FOXO binding sites, future studies will explore the mo-
lecular mechanism of DR5 induction that may involve
Foxo3a and/or other transcription factors. CHOP also
has a binding site on the DR5 gene promoter that should
be explored given recent reports of ONC201-induced
activation of the integrated stress response [30].
These studies indicate that TIC9 was much more toxic
to normal cells than ONC201/TIC10, which could be
the result of a more pronounced DR5 induction by TIC9
that may carry over into normal cells unlike prior re-
ports of ONC201/TIC10-induced DR5 in normal fibro-
blasts [26]. Clinical trials with ONC201/TIC10 have
recently commenced in advanced cancers to evaluate its
safety as a monoagent. The safety features of ONC201/
TIC10 that were a key selection criteria in this study
offer a range of clinical opportunities where genotoxicand toxic therapies are intractable. Furthermore, com-
bination therapy may be facilitated by the absence of
overlapping toxicities and broad synergy with approved
anti-cancer compounds that was recently reported for
ONC201/TIC10 [31]. Our studies cumulatively suggest
that ONC201/TIC10 is a safe and effective antitumor
agent that possesses a distinct mechanism of action that
highlights the therapeutic potential of this novel class of
anticancer drugs. This notion is further enhanced by its
chemical structure, safety, and efficacy characteristics
that are differentiated from other therapies used to treat
cancer [32,33].Methods
Cell culture and reagents
Cell lines were obtained from ATCC and cultured in
ATCC-recommended media in a humidified incubator
at 5% CO2 and 37°C. TICs were obtained from the NCI
DTP, stored at −80°C, resuspended in DMSO, and main-
tained at −20°C for storage. The following compounds
were ordered from the NCI DTP for follow up study:
TIC1 (NSC 22819), TIC2 (NSC 96682), TIC4 (NSC
160319), TIC5 (NSC 320000), TIC6 (NSC 45741), TIC7
(NSC 64408), TIC8 (NSC 250826), TIC9 (NSC 656202),
ONC201/TIC10 (NSC 350625).
Figure 7 ONC201/TIC10 and TIC9 exclusively affect Akt/ERK/Foxo3a. Western blot analysis of HCT116 p53−/− cells treated with TICs in
HCT116 p53−/− cells (5 μM, 60 hr).
Figure 6 Selection of ONC201/TIC10 as a lead TRAIL-inducing compound. Prioritization assays are shown for the process of selecting
ONC201/TIC10 as a lead compound.
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For Sub-G1 DNA content analysis, cells were trypsinized
at the indicated time points and fixed in 80% ethanol at 4°
C for a minimum of 30 minutes. Fixed cells were then
stained with propidium iodide in the presence of RNase
and analyzed on an Epics Elite flow cytometer (Beckman
Coulter). Cell viability was assessed using Cell TiterGlo
(Promega) in 96-well plates using the manufacturer’s
protocol.
Western blot analysis
Cells were treated in log-phase growth, harvested by cell
scraping, centrifuged, and lysed on ice for 2 hours with
cell-lysis buffer. The supernatant was collected following
centrifugation, and protein concentration was determined
using the Bio-Rad protein assay (Bio-Rad Laboratories).
Samples were electrophoresed under reducing condi-
tions on NuPAGE 4-12% Bis-Tris gels (Invitrogen),
transferred to PVDF, and blocked in 10% non-fat milk
in TBST for 1 hour. Membranes were then incubated
with primary antibodies obtained from Cell Signaling at
1:1000 in 2% non-fat milk in TBST overnight at 4°C.
Membranes were washed in TBST, incubated with the
appropriate HRP-conjugated secondary antibody
(Thermo-Scientific) for 1 hour, washed in TBST, and vi-
sualized using ECL-Plus (Amersham) and X-Ray film
(Thermo-Scientific).
In vivo studies
All animal experiments were conducted in accordance
with the Institutional Animal Care and Use Committee.
Athymic female nude mice (Charles River Laboratories)
were inoculated with 5X106 of cancer cells in each rear
flank as a 200 μL suspension of 1:1 Matrigel (BD):PBS.
Treatment was administered by intraperitoneal injections
at a total volume of 200 μL in DMSO. For tissue analysis,
tissue was harvested from euthanized mice and fixed in
4% paraformaldehyde in PBS for 48 hours. Tissue was
paraffin-embedded and sectioned by the Histology Core
Facility at Penn State Hershey Medical Center. H&E stain-
ing (Daiko) and TUNEL staining (Millipore) were carried
out according to the manufacturer’s protocols. TUNEL as-
sessment was carried out by manual counting of positive
cells in ten random fields of view. Bioluminescent imaging
and immunohistochemistry for TRAIL expression was
performed as previously described [26].
Microscopy
Cells were grown in chamber slides under sterile condi-
tions as indicated. At end point, cells were fixed using
BD Cytofix/Cytoperm according to the manufacturer’s
protocol. Following fixation, cells were incubated with
an anti-gamma H2AX antibody (Calbiochem DR1017) at
1:200 for 2 hours, rinsed, incubated with an Alexafluor488 secondary antibody at 1:250 for 30 minutes, stained
with Hoechst 33342 at 1 μg/mL for 5 minutes, rinsed,
and imaged.
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